Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CAVERJECT IMPULSE

« Back to Dashboard
Caverject Impulse is a drug marketed by Pharmacia And Upjohn and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug.

This drug has twenty-six patent family members in sixteen countries.

The generic ingredient in CAVERJECT IMPULSE is alprostadil. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the alprostadil profile page.

Summary for Tradename: CAVERJECT IMPULSE

Suppliers / Packagers: see list4

Pharmacology for Tradename: CAVERJECT IMPULSE

Clinical Trials for: CAVERJECT IMPULSE

The Use of Prostaglandin E1 in Head and Neck Microsurgery
Status: Recruiting Condition: Microsurgery; Head and Neck; Prostaglandin E1; Thrombosis; Complications

Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention
Status: Not yet recruiting Condition: Prostaglandin E1; Percutaneous Coronary Intervention

Prostaglandin E1 in Outpatients With Intermittent Claudication
Status: Completed Condition: Stage II Peripheral Arterial Occlusive Disease; Intermittent Claudication Fontaine Stage II PAOD

Alprostadil in Maculopathy Study (AIMS)
Status: Terminated Condition: Macular Degeneration

Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Status: Completed Condition: Peripheral Arterial Occlusive Disease

Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Status: Withdrawn Condition: Infant, Newborn; Respiratory Insufficiency; Pulmonary Hypertension; Respiratory Distress Syndrome, Newborn; Streptococcal Infections

Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
Status: Active, not recruiting Condition: Kidney Diseases; Diabetes Mellitus; Acute Kidney Injury; Kidney Failure, Chronic; Renal Insufficiency

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)
Status: Terminated Condition: Prematurity; Respiratory Insufficiency; Pulmonary Hypertension; Respiratory Distress Syndrome, Newborn

Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction
Status: Withdrawn Condition: Erectile Dysfunction

Sildenafil Citrate and Alprostadil in Treating Patients Undergoing Bilateral Nerve-Sparing Robotic-Assisted Prostatectomy for Nonmetastatic Prostate Cancer
Status: Completed Condition: Prostate Cancer; Male Erectile Disorder; Stage I Prostate Cancer; Stage II Prostate Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
INJECTABLE;INJECTION021212-001Jun 11, 2002RXNo5,716,338<disabled>Y <disabled>
Pharmacia And Upjohn
INJECTABLE;INJECTION021212-002Jun 11, 2002RXNo5,716,338<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CAVERJECT IMPULSE

Country Document Number Publication Date
New Zealand274948Feb 24, 1997
Finland953023Jun 19, 1995
Norway952442Aug 15, 1995
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn